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Abstract
Over the previous two decades, there has been a shift in the ovarian cancer paradigm to 
consider it as a multiplicity of disease types rather than a single disease, requiring spe-
cialized medical management from molecular diagnosis through to treatment. Despite 
the achieved improvements in diagnosis, surgery, and systemic treatment, ovarian can-
cer remains the leading cause of death from gynecological tumors in western countries. 
The study of ovarian cancer at a molecular level could reveal potential biomarkers of 
disease diagnosis and progression, as well as possible therapeutic targets in areas such as 
angiogenesis and homologous recombination deficiencies. Although this area of research 
is proving invaluable concerning newer therapeutic approaches, platinum-based chemo-
therapy continues to be the core of the first-line treatment. Genomic screening focusing 
on the identification of prognostic and predictive markers is considered one of the lead-
ing areas for future ovarian cancer research.
Keywords: ovarian cancer, epithelial ovarian cancer, clinics, molecular biology, 
diagnosis, treatment, prognostic biomarkers, predictive biomarkers
1. Introduction
Ovarian cancer (OC) represents almost 4% of all cancer diagnoses among women worldwide. 
It is the eighth most common cause of death by cancer, resulting in 152,000 deaths (4.3% of 
all cancer deaths) [1, 2]. Besides its low incidence, OC is associated with a high mortality rate 
attributable, in part, to the frequent diagnosis at an advanced stage. The late diagnosis of 
OC is due to several factors including symptomatology absence and/or nonspecificity to the 
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inexistence of an effective screening method and to the aggressive biology of this tumor with 
the ability to disseminate.
The geographic variability in OC incidence is considerable, being frankly higher in developed 
countries with rates surpassing 7.5/100,000 women. The highest continental rate is registered 
in Europe, where 65,584 new OC cases were observed. In opposite, the lowest continental 
values were registered in African regions, with incidence rates below 5/100,000 women [1]. 
Concerning mortality, for women with less than 75 years, the average risk of dying from OC 
is twice as high in more than less-developed regions. Inclusively, for developed countries, OC 
stands as the fifth most lethal cancer among women [1]. In Europe, in 2012, 42,749 deaths were 
observed, which corresponds to more than 25% of all worldwide OC deaths [3, 4]. Among the 
gynecological tumors, OC is the leading cause of death even being only the third most com-
mon, preceded by cervical and endometrial cancers [2–4].
Nevertheless, the numerous attempts to characterize the ovarian carcinogenesis and etiology, 
age is considered as a major determinant for OC development: there is an increased disease 
risk after the menopause, being 63 the median age at diagnosis [5].
Beyond age, an important risk factor for OC is the familiar history. Although the germline 
mutations in genes that predispose to OC are relatively rare in the general population, they 
are responsible for approximately 10–20% of all cases [6, 7]. The critical genes involved in 
hereditary OC are BRCA1 and BRCA2, associated with hereditary breast/ovarian cancer syn-
drome. The risk of spontaneous OC development, throughout life, is around 1.7%, while the 
heritage of germline mutations that alter BRCA1 gene function confers a cumulative risk from 
40 to 60%, mainly to serous carcinoma. The presence of pathogenic mutations in BRCA2 gene 
lowers the risk for about a half (10–30%). OC hereditary women tend to develop the disease 
nearly 10 years earlier than women with sporadic OC [8–10].
Moreover, reproductive and endocrine factors seem to be important, whereby the nullipar-
ity, early menarche (<12 years), late menopause (>52 years), endometriosis, polycystic ovary 
syndrome, and the recent exposure to hormone replacement treatment might be associated 
with a higher risk to develop OC [11–14]. Therefore, some behaviors and lifestyles were 
associated with a decrease in OC incidence, namely breastfeeding, multiparity, and the 
oral contraceptives use [11, 13]. Surgical procedures such as tubal ligation, hysterectomy 
with salpingectomy, and oophorectomy correlate with a lower incidence of this tumor but 
are mainly reserved for women with higher disease risk, after the completion of familiar 
planning.
Standard treatment of epithelial ovarian cancer (EOC) is based on cytoreductive surgery, fol-
lowed by platinum-based first-line chemotherapy. This neoplasia is considered chemosensi-
tive, yielding 40–60% of complete responses rates for advanced disease stages. Despite the 
apparent efficacy of treatment, up to 75% of patients will relapse and become candidates for 
second-line chemotherapy. As a result, the high percentage of late-stage diagnosis and the 
occurrence of tumor recurrence limit the treatment efficacy, and the overall 5-year survival 
rate remains only around 45%.
In the clinical practice, several pathological factors are considered prognostic for EOC patients, 
and many efforts are made to identify those that will improve patient’s stratification and be 
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useful tools for therapeutic decisions. Current research is focusing on the identification of 
both prognostic and predictive biomarkers that would help to optimize EOC treatment strate-
gies and to improve the cost-effective incorporation of emerging biological agents.
2. Clinics and diagnosis
Upon the detection of an adnexal mass suspected of malignancy, the diagnostic approach 
should be based on a careful clinical history that should include the overall physical examina-
tion, as well as gynecological, rectal, and abdominal evaluation. After the clinical evaluation, 
additional diagnostic and biochemical tests should be requested, judiciously and objectively, 
to aid in the differential diagnosis of a pelvic mass. Among the complementary diagnostic 
tests, transvaginal ultrasonography (TVU) and CA125 tumor marker determination are man-
datory [8, 12, 15]. Other markers are also used in the diagnostic investigation for suspected 
EOC cases, such as CEA and CA19.9.
In the suspicion of ovarian neoplasia, abdominal-pelvic computed tomography (CT) should 
be requested to confirm and characterize the presence of lesions, to evaluate the tumor 
extension, to identify unresectable disease, and to exclude nonovarian metastatic disease. 
Nevertheless, the EOC diagnosis is surgical as only the anatomopathological exam confirms 
the definitive diagnosis. Diagnostic radiologically guided aspiration/biopsy or laparoscopy 
should be requested, whenever neoadjuvant chemotherapy is being considered [8, 16].
Late disease diagnosis explains, in part, the high mortality rate of these patients [12, 17]. 
Over the past 25 years, there has been little improvement in the survival rate, being around 
37% in the early 1970 and 44% in 2000, despite the advances in the medical treatment [18]. 
However, the currently available tests lack adequate sensitivity and specificity, promoting 
a noneffective screening strategy. Prospective studies have shown that the combined use of 
serum CA125 and TVU improved the specificity of the tests and allowed the detection of a 
number of OC cases in the preclinical phase (this is discussed in detail in another chapter).
3. Histopathology
Ovarian tumors are classified according to the World Health Organization (WHO) proposal 
for gynecological tumors. Ovarian cancer has high cellular heterogeneity, and most of the 
primary ovarian tumors can be integrated into three major groups, namely epithelial, sex cord 
and ovarian stroma, and germ cell tumors [2].
Although the ovarian epithelial surface represents only a small fraction of all ovarian cell 
types, EOC is the most common, corresponding to almost 60% of all ovarian tumors [19, 
20]. According to the criteria proposed by the WHO in 2014, EOC can be divided into seven 
histological subcategories, namely serous, mucinous, endometrioid, clear cell, Brenner, sero-
mucinous, and undifferentiated [2]. All the mentioned histological subtypes, except for the 
undifferentiated type, are further subdivided into benign, borderline, and malignant neopla-
sia, depending on the optical microscopy characteristics.
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Sex cord and stroma tumors arise from the ovarian connective tissue, often responsible for 
hormone secretion. These tumors encompass a vast group of tumors, for which the subgroup 
of “pure” ovarian stromal tumor is the most frequent (9% of all OC), usually with benign 
behavior. Also in this group of tumors, granulosa cell tumors are associated with aggressive 
behavior and represent 1% of all OC. Regarding the germ subgroup, a mature cystic teratoma 
is very common (32% of all OC), although the remaining germ cell tumors, both benign and 
malignant, are rare, representing 3–5% of all OC cases [2, 21].
4. Staging
Ovarian cancer staging is surgical, being performed according to the International Federation 
of Gynecology and Obstetrics (FIGO) criteria [22]. CT or magnetic resonance imaging scans, 
although of limited impact for OC early diagnosis, allow to establish a surgery plan and to 
determine tumor irresectability criteria for 70–90% of all patients. The ability to detect peri-
toneal implants in both exams depends upon their location, size, and the presence of ascites. 
However, CT is the imaging modality of choice for OC staging, since it is indispensable for the 
preoperative evaluation to optimize maximal cytoreduction surgery or to help in the decision 
of neoadjuvant chemotherapy.
Ovarian cancer dissemination can occur through all known propagation routes, i.e., lym-
phatic, hematogenic, transcavitary, and contiguous. The transcavitary course is undoubtedly 
the most clinically relevant and, in the vast majority of cases, has an impact on the patient 
prognosis [23, 24]. The dissemination to the peritoneal cavity is an early phenomenon in the 
natural history of the disease, since the malignant cells follow the peritoneal fluid, flow con-
cerning intra-abdominal pressure variations. Ovarian cells are characterized as anchorage-
dependent cells, meaning that they could only survive when adherent to the extracellular 
matrix or in contact with neighbor cells. However, when OC cells exfoliate into the perito-
neal cavity, they can avoid anoikis (apoptosis process triggered by the loss of binding to the 
extracellular matrix) and survive even when isolated. Cancer cells in this state can survive 
and disseminate into the peritoneum, depositing accordingly to the passive flow distribution 
of peritoneal fluid, predominantly into the paracolic gutters, diaphragmatic surfaces, liver 
capsule, intestine surface, and omentum. The adhesion of malignant cells to the peritoneum 
precedes the local invasion and the secondary metastasis, namely to the pleural cavity by the 
transdiaphragmatic pores (Stage IV) [25]. The transcavitary route seems to be related to the 
OC cells predilection for the abdominal cavity (homing) rather than the deposition in other 
organs such as liver, lungs, brain, or bone (rarely in these latter two locations). The dissemina-
tion by contiguity is also important and of particular interest for organs like fallopian tubes, 
uterus, contralateral appendix and bladder, rectum, and pouch of Douglas. The iatrogenic 
route by contiguity, for example, to the abdominal wall is less frequent. Lymphatic dissemi-
nation is frequently observed when the disease is confined to the ovary, being found in almost 
15% of FIGO I–II cases [26]. In fact, for a proper FIGO staging, lymphadenectomy is required, 
and the removal of bulky lymph nodes should be performed to achieve complete macroscopic 
resection. Although the systematic lymphadenectomy in advanced OC surgical management 
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is still discussed, it has an impact in early disease stages not only to define FIGO staging but 
also to establish the need for adjuvant treatment, with a significant impact in survival [27, 28]. 
Blood dissemination is less frequent and usually occurs in advanced disease stages [23, 24].
5. Prognostic factors
A considerable number of clinical-pathological factors have been implicated in OC prognosis. 
Disease stage, tumor size, histological subtype, differentiation degree, and residual tumor 
after surgery are considered as the classic prognostic factors. More specifically, the extent of 
residual disease after surgery is regarded as a major prognostic factor, shown to influence the 
chemotherapy response and survival [29–33]. Inclusively, a recent meta-analysis has shown 
that residual tumor is a more powerful prognostic determinant than FIGO stage [31]. The 
correct histological classification of EOC is also crucial, since it is an independent prognostic 
factor and provides a guideline for therapeutic management [8, 27]. Performance status (PS) 
and age are also important factors having an impact on the prognosis and, ultimately, in the 
decision of medical treatment [27].
Numerous studies have been conducted to assess the clinical significance of molecular altera-
tions in OC. However, so far, the obtained results do not allow a prognostic biomarker to be uni-
versally accepted, although the determination of BRCA germline mutations has been recently 
approved as a predictive biomarker for OC. Recently, the development and the application of 
new genomic technologies have allowed the description of molecular signatures integrated into 
prognostic and predictive models. In particular, the Cancer Genome Atlas Project (TCGA) has 
been critical in adding to our knowledge, as it has been used to confirm the importance of BRCA 
genes to serous OC patients survival, as well as being able to help to describe a transcriptional 
signature with prognostic relevance [34] (this will be investigated further in a separate chapter).
6. Treatment
6.1. First-line treatment
The therapeutic strategy for EOC is based on cytoreductive surgery and staging, followed 
by adjuvant chemotherapy with the duplet platinum/taxane [8, 20]. As mentioned above, the 
extent of surgery is a determinant for survival and response to chemotherapy, since these 
parameters vary significantly depending on the success (optimal or suboptimal) of the surgical 
procedure [33]. Systemic therapy with cytotoxic agents plays a fundamental role in the treat-
ment of this neoplasia. Chemotherapy is generally recommended in the EOC, including early 
stages with histopathological criteria of poor prognosis (FIGOIA/IB G3, FIGO IC, FIGO II, or 
clear cell histology at any stage). However, stage IA or IB G1 or G2 tumor patients, if adequately 
staged (i.e., with peritoneal washings, assessment of the contralateral ovary and fallopian tube, 
pelvic and para-aortic node assessment and omentectomy), have a better prognosis and can 
be treated with surgery alone without the need for adjuvant chemotherapy [35–37] (Figure 1).
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The last decades have brought significant advances in the medical treatment of EOC. The 
association of paclitaxel with platinum has been shown to prolong both progression-free sur-
vival (PFS) and overall survival (OAS) of advanced stage patients when compared to the 
previous nontaxane treatment regimens. Globally, the inclusion of paclitaxel in the adjuvant 
chemotherapy scheme resulted in a 30% reduction in the risk of death [38–40]. Thus, the intra-
venous combination of paclitaxel (175 mg/m2) and carboplatin (AUC 5–7.5), every 3 weeks, 
for six cycles, was established as the standard primary adjuvant chemotherapy for advanced 
stage disease, after cytoreductive surgery (Figure 1) [8, 38, 39, 41–43].
This treatment regimen has been the standard for more than 15 years, and the clinical trials 
conducted in the last decades for the introduction of a third agent, as in the ICON-5/GOG182 
Figure 1. EOC first-line treatment algorithm according to the clinical trial that determines their approval.
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clinical trial, have not shown any improvement in the survival [44]. For patients that develop 
allergy or toxicity to paclitaxel, namely hypersensitivity or neurotoxicity, the combination of 
docetaxel/carboplatin or pegylated liposomal doxorubicin (PLD)/carboplatin can be consid-
ered as an alternative [42, 45]. The cisplatin/paclitaxel duplet is equally valid but associated 
with increased toxicity and less convenience in the administration, being currently reserved 
for patients who have developed hypersensitivity to carboplatin [8, 41].
The inclusion of bevacizumab, an anti-VEGF (Vascular Endothelial Growth Factor) monoclo-
nal antibody, is recommended for advanced OC patients with poor prognostic characteristics 
(Stage IV or suboptimal resection). This targeted therapy should be administrated concomi-
tantly with paclitaxel/carboplatin (after the first cycle) and be maintained after the six cycles 
of chemotherapy. Regarding the dose and duration of maintenance, the results are not clear, 
although a similar benefit is obtained with the administration of 7.5 mg/kg and 15 mg/kg for 
12 and 15 months, respectively [46, 47]. Although not licensed in the United States of America 
and not consistently used in Europe, bevacizumab was approved by the European Medicines 
Agency (EMA) at a dose of 15 mg/kg for 22 cycles (15 months) [8, 46].
To improve the efficacy of the primary treatment, several clinical trials have evaluated the 
addition of a third cytotoxic agent (such as epirubicin, topotecan, gemcitabine, or PLD) to 
the first-line regimen, but none have demonstrated a benefit for triplets [8]. In addition, the 
Japanese JGOG-3016 trial evaluated the impact of a dose-dense therapeutic regimen (pacli-
taxel, weekly, 80 mg/m2) on the chemotherapy effectiveness for OC patients. The results were 
promising for the benefits in PFS and OAS although associated with higher toxicity, especially 
myelotoxicity. Although it was a trial with potential impact on the clinical practice, because 
of the pharmacogenetic differences between the Japanese and Caucasian populations, further 
study was required to confirm these results. The European MITO-7 study did not confirm 
these findings in Caucasian patients, showing no benefit in the PFS and OAS with the weekly 
carboplatin (AUC 2) and paclitaxel (60 mg/m2) regimen [48]. In the absence of new data, pacli-
taxel dose-dense administration can only be considered as an option [8].
Clinical data demonstrate that, despite the high response rate to the first-line treatment, a 
significant proportion of OC patients will develop disease recurrence, which in most cases 
is confined to the abdominal cavity. Based on this particular feature, intraperitoneal chemo-
therapy administration was associated with an improvement in PFS and OAS in phase III 
randomized studies (GOG 104, 114 and 172), in combination with intravenous chemotherapy 
[49, 50]. However, this strategy is not widely used in clinical practice due to its high toxicity 
[8]. Chemotherapy administered directly in the abdominal cavity might also be performed 
in the surgical setting using hyperthermal intraperitoneal chemotherapy (HIPEC). The jus-
tification for the use of the last therapeutic approach is based on studies that demonstrated 
that high temperatures help to overcome the resistance to cisplatin, as a result of increased 
penetration and cellular accumulation of this drug when administrated intraperitoneally in 
association with hyperthermia [51]. Although it represents a promising strategy, the use of 
HIPEC remains controversial.
Numerous studies have shown that neoadjuvant chemotherapy is feasible in advanced 
disease (Stage IIIC–IV), for which the disease is considered unresectable or when  optimal 
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primary cytoreduction is not possible due to the disease extension and/or comorbidi-
ties that increase the surgical risk [30, 52]. Neoadjuvant chemotherapy is associated with 
some advantages, including tumor size and disease extension reduction, improvement 
of optimal cytoreduction rate, less extensive surgery with lower morbidity/mortality, 
improvement of patients’ PS before surgery, and evaluation of tumor chemosensitivity. 
The chemotherapy scheme to be applied should be based on platinum (often a paclitaxel/
carboplatin combination), and it is not recommended to perform more than 3–4 cycles to 
avoid the emergence of resistant clones [8, 30]. Consequently, the use of primary chemo-
therapy with interval surgery has become widely accepted, whereas the role of second-
ary interval debulking surgery after primary surgery (suboptimal cytoreduction and three 
cycles of chemotherapy) is less clear, as improved survival was reported by the European 
Organization for Research and Treatment of Cancer (EORTC) trial [32] but not confirmed 
by the Gynecological Oncology Group (GOG) [53]. Also, the “second look” diagnostic lap-
aroscopy or laparotomy to evaluate the intraperitoneal condition is obsolete and should 
not be considered an option [8].
6.2. Recurrent disease treatment
The maximal surgery resection strategy combined with adjuvant chemotherapy achieves 
complete clinical remission in about 75% of EOC patients. However, after 12–18 months, 
approximately 75% of these patients will develop recurrent disease and be subjected to fur-
ther treatment. The OC recurrence is defined according to the progression-free interval (PFI) 
after the end of the initial treatment (Figure 2) [8, 21, 41, 54–56].
The prognosis and the likelihood of response to second-line therapy (and subsequent lines) 
are dependent on the PFI after the last cycle of the previous chemotherapy line. This cat-
egorization defines “platinum-refractory,” when disease progresses during therapy or 
within 4 weeks after the last cycle; “platinum-resistant,” whose progression occurs within 
6 months after platinum therapy completion; “partially platinum-sensitive,” for disease 
which progression occurs between the 6 and 12 months; and “platinum-sensitive,” whose 
progression occurs in a period superior to 12 months [57]. The biological behavior of tumors 
in these groups is quite variable, with distinct response rates and variable symptoms with 
different treatment needs. If relapse occurs 6 months after the completion of first-line che-
motherapy, a platinum-based regimen should be performed, since the disease is consid-
ered platinum sensitive. For patients with platinum-sensitive relapses, there are several 
therapeutic strategies available which, since this phenomenon can occur repeatedly, allows 
the selection of different therapeutic combinations [8]. However, the time to subsequent 
relapse will be progressively shorter until the tumor becomes virtually resistant to these 
agents [21].
The platinum re-administration is associated with a response rate around 30%, similar to the 
improvement seen in the PFI. Available treatment options for OC platinum-sensitive relapse 
are ideally based on the association of platinum with paclitaxel, gemcitabine (with or without 
bevacizumab), or with PLD [58–62] (Figure 2). The therapeutic scheme selection should con-
sider the toxicity profile of each regimen, the residual toxicities of the previous regimens, and 
the patients’ preferences.
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Figure 2. EOC recurrence treatment algorithm based on platinum-free interval, according to the clinical trial that deter-
mines its approval.
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The administration of bevacizumab in combination with carboplatin/gemcitabine, followed 
by maintenance until progression or toxicity, was approved by EMA as the first-line treat-
ment for platinum-sensitive relapse (for bevacizumab-naïve patients), being associated with 
an improvement in PFS despite no impact on OAS [8, 63]. In December 2016, US Food and 
Drug Administration (FDA) also approved bevacizumab administration to platinum-sensi-
tive recurrent patients, either in combination with carboplatin/paclitaxel or carboplatin/gem-
citabine, followed by bevacizumab alone.
Patients with PFI between 6 and 12 months, considered as partially sensitive, also benefit from 
platinum-based second-line therapy, although with a lower therapeutic effect (Figure 2). For 
these patients, the administration of trabectedin associated with PLD might also be an option, 
according to the results of the OVA301 trial, probably by restoring platinum sensitivity due to 
the artificial prolongation of the platinum-free interval [8, 64].
For relapses linked to a disease-free interval less than 6 months, the tumor is defined as plati-
num resistant and another treatment strategy should be instituted, with monotherapy regi-
mens being recommended [8, 40, 65]. The treatment of platinum-resistant/refractory patients 
is mostly directed toward improvement in the quality of life and symptom control, as these 
patients are usually associated with a reduced prognosis with a reduced OAS (generally 
less than 12 months) [8]. Surgery as a therapeutic alternative in these cases might be consid-
ered only in need of symptom palliation. Monotherapy regimens with paclitaxel (preferably 
weekly), PLD, gemcitabine, and topotecan, among others, have shown similar response rates 
(not exceeding 15%) and PFS between 3 and 4 months [8, 66–73]. Thus, the choice for one of 
these agents should be based on previously performed therapies, toxicity profiles, adminis-
tration convenience, cost, and patient opinion. Combination therapy regimens did not signifi-
cantly improve response rates or survival for platinum-resistant disease, when compared to 
monotherapy regimens, even when considering toxicity [8, 40].
Recently, promising results have been achieved with biological maintenance treatments, 
in particular with anti-angiogenic agents (bevacizumab, pazopanib, and trebananib) and 
PARP (poly(ADP-ribose) polymerase) inhibitors (olaparib, niraparib, and rucaparib) [74]. 
Bevacizumab was the first antiangiogenic agent to demonstrate clinical benefit in plati-
num sensitive and resistant relapse, concomitantly with chemotherapy and as maintenance 
therapy. As previously mentioned, according to the results published in the OCEANS trial, 
EMA approved the combination of bevacizumab with carboplatin/gemcitabine for patients 
with platinum-sensitive OC relapse, if there was no previous exposure to this antiangiogenic 
drug [63]. According to the AURELIA results, the addition of bevacizumab to the chemo-
therapy (weekly paclitaxel, PLD or topotecan) in patients with platinum-resistant OC (pre-
viously treated with up to two therapeutic lines) has been shown to be associated with an 
improvement in PFS, response rates, and quality of life, although without impact on OAS 
[75]. Therefore, this regimen could be an alternative in this subgroup until the development 
of toxicity or progression (Figure 2).
In addition to bevacizumab, olaparib is also considered as a target therapy option in OC 
recurrence. This drug was the first PARP inhibitor to be authorized by EMA as maintenance 
treatment of BRCA-mutated patients, with partial or complete responses to platinum-based 
chemotherapy. The results have shown almost a 7-month extension in PFS for patients with 
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BRCA mutations exposed to Olaparib (11.2 versus 4.3 months; HR, 0.18), although the impact 
on OAS was not observed [76]. Response rates to this drug correlate with the platinum-free 
interval, being 69.2, 45.8 and 23.1% for the sensitive, resistant, and platinum-refractory dis-
ease, respectively [77]. Furthermore, olaparib administration allows for a time extension for a 
subsequent therapy which suggests that its administration did not adversely affect the treat-
ment recurrence.
With the existence of several treatment alternatives that allow for sequential approaches and 
the emergence of new targeted therapies, most of which are well tolerated, it is possible to 
administrate extended therapeutic regimens concomitantly with significant symptomatic 
control and a positive impact in the quality of life.
6.3. Emergent therapeutic approaches
The duplet platinum/taxane is considered the standard first-line therapy for advanced OC 
treatment. Nevertheless, chemotherapy response rates remain disappointing, and the intro-
duction of newer treatment strategies at recurrence is essential to increase the long-term sur-
vival. The recent adoption of molecular therapies targeting the inhibition of angiogenesis and 
DNA repair is a step forward in the OC medical treatment, aiming to delay disease pro-
gression and the re-treatment with chemotherapy [33]. The encouraging study results with 
bevacizumab, in first-line treatment and both platinum sensitive and resistant recurrence, 
illustrate the importance of angiogenesis inhibition in the success of OC treatment [46, 63, 75].
PARP is an enzyme involved in the response to DNA single-strand breaks, and so it was ini-
tially suggested that its inhibition could be used to enhance the effects of chemotherapy [78]. 
However, the finding that the survival of tumor cells carrying BRCA homozygous deletions 
is significantly lower with the administration of PARP inhibitors prompted the development 
of a new therapeutic strategy for OC [79, 80]. The molecular rationale for this association is 
based on the fact that cells with BRCA defective proteins are not able to repair DNA double-
strand breaks by homologous recombination (HR), depending on other pathways to repair 
the damage, namely the base excision repair (BER) pathway, in which PARP is involved. In 
the BER pathway, PARP is responsible to detect single-strand breaks and to activate effector 
proteins to repair the damage. Thus, homologous recombination deficiencies (HRD), as in 
the presence of BRCA mutations, in concomitance with PARP inhibition lead to cell death 
due to the excessive accumulation of unrepaired damage. This phenomenon is designated as 
synthetic lethality and occurs when two nonlethal defects are combined to culminate in cell 
death. This strategy is also of benefit in that toxicity is reduced for normal tissues, as nontu-
mor cells can repair DNA by the HR pathway [80, 81].
As molecular and genetic knowledge of OC is increasing, studies with PARP inhibitors are 
indicating that more patients with OC may benefit. According to data published by the TCGA 
project, the presence of BRCA mutations is identified in about 20% of high-grade serous ovar-
ian cancer (HGSOC), and about 50% of these tumors have a positive HRD phenotype, even 
in the absence of a familial history of breast/ovarian cancer [34, 78]. In addition to the excel-
lent results obtained with olaparib for the subgroup of patients with BRCA mutations, the 
study published by Ledermann et al. also demonstrated that PARP inhibition is also useful 
for BRCA wild-type patients, although to a less extent [76].
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The promising results achieved with olaparib encouraged the development of new PARP 
inhibitors, including niraparib and rucaparib [82, 83]. Maintenance clinical trials ongoing 
with both agents include BRCA wild-type patients to test the effect of PARP inhibitors in 
this major group, incorporating additional molecular tests for HDR. Namely, for patients 
with platinum-sensitive recurrence, the PFS mean duration is significantly higher for patients 
receiving niraparib when compared to placebo, regardless of the presence/absence of BRCA 
germline mutations or HRD status [83]. Thus, clinical trials are being developed to evaluate 
not only the impact of PARP inhibitors on limiting recurrence, as in the SOLO2 trial [84], 
but also as a maintenance strategy for first-line treatment, as in SOLO1 [85]. In addition, the 
GOG3005 trial evaluates the addition of the PARP inhibitor veliparib to first-line therapy (car-
boplatin/paclitaxel), as well as its role in subsequent maintenance [78].
A possible synergy between PARP inhibitors and other pathways inhibitors, such as anti-
angiogenic, has also been hypothesized. In fact, preclinical studies have demonstrated an 
additive effect on the association of inhibitors of these two pathways, since hypoxia leads to 
a decreased expression of DNA repair proteins, thereby increasing the sensitivity for PARP 
inhibitors [86, 87]. Thus, a recent phase I clinical trial, which combined a tyrosine kinase inhib-
itor of VEGF receptor, cediranib, with olaparib, achieved an objective response rate of 44% in 
recurrent disease [88]. The results of this study prompted the development of a randomized 
phase II trial, demonstrating an improvement in PFS and in the objective response rate for the 
cediranib/olaparib combination when compared to olaparib alone (17.7 versus 9.0 months; 
HR, 0.42; 95% CI, 0.23–0.76; P = 0.005 and 79.6% versus 47.8%; OR, 4.24; 95% CI, 1.53–12.22; 
P = 0.002) in patients with platinum-sensitive recurrence [89]. Although the results must be 
interpreted carefully, due to the low number of recruited patients, they are of high interest as 
it suggests a synergistic action for the combined use of angiogenesis/DNA repair inhibitors. 
Thus, numerous clinical trials exploring these pathways are under development, either iso-
lated or in combination, for first-line therapy or maintenance, with the prospect of increasing 
the treatment opportunities for OC patients.
6.4. Monitoring treatment response
The treatment response evaluation in OC is based on CT, following RECIST criteria, comple-
mented by the CA125 serum measurement following Gynecologic Cancer InterGroup (GCIG) 
criteria [90]. In fact, despite the limitations as a diagnostic biomarker, CA125 is a good pre-
dictor of relapse as it proved to be a useful biomarker for monitoring treatment response in 
more than 80% of OC patients [91]. Normalization of CA125 serum levels following first-line 
therapy does have clinical implications, especially when considering maintenance treatment 
in OC. However, even the systemic therapy in early recurrence stages had the potential to 
improve survival, studies have demonstrated that the premature treatment in asymptomatic 
patients with single elevation of CA125 levels (without clinical or radiological evidence) had 
no positive impact [92].
In Medical Oncology clinical practice, high heterogeneity in the response and toxicity to cyto-
toxic agents are observed. There are subgroups of patients who, despite being at an early 
disease stage, have a higher risk of tumor progression. In these cases, surgery and classic 
prognostic factors do not allow to predict the biological behavior of these tumors correctly. In 
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the current era of individualized therapy, and according to the OC heterogeneity, biomarkers 
need to be developed to identify patients at an early disease stage but with the potential to 
progress and disseminate [93].
6.5. Predictive factors
Several biomarkers are considered to have prognostic relevance, independent of the thera-
peutic approach. In OC, as previously mentioned, FIGO staging, histological subtype, or the 
extent of residual disease are considered as key prognostic factors. The identification and 
characterization of predictive biomarkers for OC have proven to be a challenge, and none 
of the molecular determinants that underlie platinum-sensitivity/resistant phenotypes have 
reached the clinical setting [91].
Additionally, the inability to select those patients that will benefit from bevacizumab to maxi-
mize survival and minimize toxicity and costs complicates treatment planning. Several stud-
ies have been performed to unravel the role of the VEGF signaling pathway and the key 
drivers of response to antiangiogenic agents in OC. VEGF serum levels are thought to be 
representative of the VEGF-mediated OC angiogenesis, but the results were not systemati-
cally concordant [94]. Also, VEGFR-2 plasma levels were not predictive for patients treated 
with bevacizumab in the GOG-218 trial [95]. Translational research conducted within the 
ICON7 trial identified three candidate biomarkers (mesothelin, VEGFR-3, and alpha-1-acid 
glycoprotein) for patients treated concomitantly with this antiangiogenic agent and first-line 
chemotherapy. Each of these biomarkers was considered as an independent factor and, in 
combination with CA125 measurement, was included in a predictive nomogram for bevaci-
zumab [96]. However, though several promising candidate angiogenesis biomarkers for OC 
were identified, it was neither possible to achieve meaningful results for their use in routine 
clinical practice nor possible to select patients for this targeted therapy [97, 98].
Failure to improve the therapeutic strategies in OC has resulted in studies focusing on genomic 
features, such as the TCGA project. This project aims to determine the impact of OC genomic 
and epigenomic changes and, thus, to identify molecular markers influencing clinical out-
come and possible therapeutic targets for OC. One of the most interesting findings obtained 
from this study is the presence of HRD in about 50% of HGSOC, which could represent a 
patient subgroup which could benefit from PARP inhibitor treatment [34]. In fact, the pres-
ence of BRCA mutations and an HRD positive phenotype is both positive predictive factors 
for PARP inhibition, thus indicating personalized OC therapy defined by a genetic biomarker 
[76, 83]. The impact of BRCA mutations as predictive biomarkers has been published for other 
agents such as PLD and trabectedin [99, 100]. The implications of these advances are still 
being investigated, and as a result, genetic testing for BRCA mutations should be offered for 
all patients with nonmucinous tumors, regardless of age or familial history. The test should 
be performed at diagnosis, as it provides information on the likelihood of response to che-
motherapy and can then be systematically incorporated into clinical practice to promote an 
individualized therapeutic strategy [33]. The TCGA project also provided the opportunity to 
identify four OC subtypes based on the expression of marker genes (differentiated, immuno-
reactive, mesenchymal, and proliferative), and several retrospective subanalyses have already 
demonstrated that is possible to correlate distinct outcomes between the subgroups [101, 102].
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Based on the TCGA data, other studies have also proposed molecular signatures, namely the 
prognostic model “Classification of Ovarian Cancer” (CLOVAR), for which 23 genes involved 
in the platinum-induced DNA damage repair are predictive of treatment response among 
HGSOC patients [103]. Recently, the ARIEL2 clinical trial showed that the combination of 
BRCA mutational status with the degree of genome-wide loss of heterozygosity (LOH) in the 
tumor could predict the rucaparib treatment response. BRCA-mutated patients (germline or 
somatic) or BRCA wild-type with high LOH had longer PFS and clinical response to rucapa-
rib, when compared with BRCA wild-type and low LOH patients [104].
The concept of BRCAness must be promptly clarified, as the associated phenotypes define 
a clinical subpopulation of EOC patients with common characteristics. These include high 
response rates to both first-line platinum-based treatment and to relapse therapies (includ-
ing platinum based), long treatment-free intervals (even in recurrent disease), and improved 
OAS and include mainly serous tumors. The HRD phenotype (somatic or germline) might 
be complemented with other molecular defects, beyond BRCA deficiencies, which lead to 
an analogous clinical profile and be targeted for PARP inhibition [34, 105]. Commercial tests 
are already available, and multiple clinical trials (as ARIEL3 and NOVA) are ongoing to 
investigate PARP inhibition in BRCA wild-type patients and to identify a putative predictive 
signature.
7. Pharmacogenomics for future predictive marker definition
Although BRCAness signature definition can provide valuable information regarding the 
magnitude of the benefit of targeted therapy, these biomarkers may not be unique for the 
determination of the likelihood of treatment sensitivity/resistance. To date, besides BRCA 
mutations and HRD status, platinum sensitivity remains the best biomarker of PARP inhibi-
tor response. Platinum sensitivity correlates with HRD, and platinum-sensitive tumors are 
more responsive to PARP inhibitors than platinum-resistant tumors, whatever the genetic 
background [33, 78]. Therefore, perhaps the PARP inhibitors administration should be offered 
to all OC patients that respond to platinum-based treatment.
Platinum-based compounds are among the most active and used cytotoxic agents in the clini-
cal practice. They exert their biological effect by acting as alkylating agents by the ability to 
covalently bind to DNA, leading to the formation of intrastrand and interstrand DNA adducts 
that promote cell-cycle arrest and tumor cell apoptosis. The mechanisms underlying the 
development of chemoresistant phenotypes in OC are not fully recognized. Interindividual 
variation in platinum-drug response might be a major determinant for OC. This is suggested 
from the wide variability in the PFI and its direct association with a platinum response, as 
well as the finding that intrinsic resistance to these compounds, occur in up to a fifth of OC 
patients [106–109]. Mechanisms involved in platinum resistance are likely to be multifactorial 
although seems to be greatly determined by the platinum detoxification pathway and DNA 
damage repair ability [54, 108, 110–113].
While platinum therapy is prescribed to achieve a target exposure based on renal function, 
the dose of taxanes is based on body surface area. Taxanes are microtubule-stabilizing drugs, 
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inducing cell cycle arrest and activating proapoptotic signaling. The cellular toxicity to tax-
anes is controlled by the action of multiple mediators, namely those involved in transport (i.e., 
ABCB1, ABCC1, and ABCC2), metabolism, and metabolism-associated proteins (cytochrome 
P450s and nuclear receptors), as well as pharmacodynamics (i.e., TP53 and CDKN1A), which 
appear to play a role in taxane efficacy [54, 108, 114–116]. However, to date, no reliable bio-
marker or signature exists to predict the sensitivity or resistance to paclitaxel. Although 
the duplet platinum/taxane is associated with better outcome, rather than platinum alone, 
the results of the GOG132 trial showed that only 42% of patients are likely to benefit from 
paclitaxel administration [117], and thus, further study into the mechanisms of resistance is 
needed.
8. Conclusion
Achieving an individualized therapeutic strategy will only be possible through the identi-
fication of feasible, validated, and reproducible biomarkers in the clinical practice that will 
allow the prediction of the likelihood of response to a given treatment. Biomarker validation 
is crucial, both in respect of predictive ability and sensitivity/specificity, and should be stated 
previously in the definition of treatment subgroups [106, 107, 118, 119].
Research in OC treatment evolution and improvement needs to focus on the identification 
of interindividual determinants, which is often associated with genetic polymorphisms to 
identify potential biomarkers and/or treatment targets. Circulating tumor cells or tumor 
nanovesicles (as exosomes) may help to identify the molecular targets. Consequently, the 
incorporation of molecular and genetic information into integrated clinical models may be 
a potential approach in order to define predictive nomograms. Pharmacogenomics will be 
important in clinical practice to improve efficacy, reduce toxicity, and predict nonresponders 
to several therapies, thus allowing for individualized treatment strategies.
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